Inhibition of NOS was recently shown to have tumor antivascular activity in patients with PCa [63], and the efficacy of NO-releasing drugs for BPH and lower urinary tract symptomatology was evaluated in a clinical trial based on the rationale that NO can relax muscular tone [64]. This evidence concerns the gene NOS1 and posterior cortical atrophy.